To include your compound in the COVID-19 Resource Center, submit it here.

Bayer's anetumab ravtansine misses in Phase II for mesothelioma

Bayer AG (Xetra:BAYN) reported data from a Phase II trial in 248 patients with malignant pleural mesothelioma (MPM) showing

Read the full 195 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE